Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes
Information source: University of Roma La Sapienza
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Type 2 Diabetes Mellitus; Hypercholesterolemia
Intervention: Atorvastatin (Drug); Placebo (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: University of Roma La Sapienza Official(s) and/or principal investigator(s): Stefania Basili, Prof., Principal Investigator, Affiliation: Sapienza-Univerity of Rome
Summary
Primary and secondary prevention trials with statins, as well as with antiplatelet, clearly
demonstrated that these drugs are able to reduce cardiovascular events. Even if the
principal mechanism of action of statins is to lower cholesterol, other effects, the
so-called pleiotropic effects, have been considered as adjunctive properties potentially
accounting for the anti-atherosclerotic effect of statins.
Inhibition of oxidative stress may be considered an intriguing pleiotropic effect in view of
the fact that oxidative stress is thought to be a key event in the initiation and
progression of atherosclerotic disease. Reduction of several markers of oxidative stress
including isoprostanes, 8-hydroxydeoxyguanosine (8-OHdG), and nitrotyrosine have been
observed after statin treatment. NADPH oxidase is among the most important sources of
reactive oxygen species involved in atherosclerotic disease. The investigators developed an
ELISA to evaluate serum levels of soluble-gp91phox, the catalytic core of phagocyte NADPH
oxidase. Recently the investigators showed that statins (30 days treatment) exert an
antioxidant effect via inhibition of soluble gp91phox expression.
The exact mechanism by which atorvastatin reduces NADPH oxidase, however, is unclear. Recent
study showed that statin treatment inhibits leukocyte ROCK activity, a protein kinase
implicated in the activation of NADPH oxidase, with a mechanism that seems to be independent
from lowering cholesterol. To further study the mechanism(s) implicate in gp91phox
downregulation by statin the investigators planned the present study in patients with high
risk of vascular events such as hypercholesterolemic and Type 2 Diabetes mellitus patients.
In addition the investigators want to evaluate the synergistic role of atorvastatin with
aspirin treatment.
Clinical Details
Official title: Effects on Oxidative Stress, Coagulation, Platelet Activation and Inflammatory Indexes of Atorvastatin and/or Aspirin Treatment in Patients at High Risk of Vascular Events
Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Evaluation of effect of Atorvastatin Therapy in Hypercholesterolemic Patients (n=30) and Diabetic Patients (n=30)
Detailed description:
Primary and secondary prevention trials with statins, as well as with antiplatelet, clearly
demonstrated that these drugs are able to reduce cardiovascular events. Even if the
principal mechanism of action of statins is to lower cholesterol, other effects, the
so-called pleiotropic effects, have been considered as adjunctive properties potentially
accounting for the antiatherosclerotic effect of statins.
Inhibition of oxidative stress may be considered an intriguing pleiotropic effect in view of
the fact that oxidative stress is thought to be a key event in the initiation and
progression of atherosclerotic disease. Reduction of several markers of oxidative stress
including isoprostanes, 8-hydroxydeoxyguanosine (8-OHdG), and nitrotyrosine have been
observed after statin treatment. NADPH oxidase is among the most important sources of
reactive oxygen species involved in atherosclerotic disease. The investigators developed an
ELISA to evaluate serum levels of soluble-gp91phox, the catalytic core of phagocyte NADPH
oxidase. Recently the investigators showed that statins (30 days treatment) exert an
antioxidant effect via inhibition of soluble gp91phox expression.
The exact mechanism by which atorvastatin reduces NADPH oxidase, however, is unclear. Recent
study showed that statin treatment inhibits leukocyte ROCK activity, a protein kinase
implicated in the activation of NADPH oxidase, with a mechanism that seems to be independent
from lowering cholesterol.
Accelerated atherosclerosis is a typical feature of type 2 diabetes mellitus (T2DM). Thus,
patients with T2DM have a 2- to 4-fold increased risk of cardiovascular diseases (CAD) and
2- to 6-fold increased risk of stroke.
Platelets play a major role in the etiology of atherosclerotic disease, as shown by the
significant decrease of cardiovascular events in patients treated with aspirin, an inhibitor
of COX1 that prevents platelet thromboxane (Tx) A2 formation. Despite this, interventional
trials with aspirin in diabetic patients failed to show a beneficial effect. It has been
previously demonstrated that COX1 inhibition determines a shift in arachidonic acid
metabolism towards other pathways, such as the lipooxygenase system. The investigators
speculate that COX1 inhibition could also be associated with increased conversion of
arachidonic acid to platelet isoprostane formation; the increase of platelet isoprostanes
would balance the inhibition of TxA2, thus hampering the antiplatelet effect of aspirin. As
reported above, statins have been reported to down-regulate systemic isoprostanes with a
mechanism that may involve inhibition of NADPH oxidase,therefore it could be interesting to
examine if statins improve the antiplatelet effect of aspirin via inhibition of platelet
isoprostanes.
To further study the mechanism(s) implicate in gp91phox downregulation by statin the
investigators planned the present study in patients with hypercholesterolemia.
Furthermore, the second part of the study will be addressed to evaluate the synergistic role
of atorvastatin with aspirin treatment in Type 2 Diabetes mellitus patients.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
For Hypercholesterolemic patients:
Inclusion Criteria:
- Patients with polygenic hypercholesterolemia (LDL-C > 160 mg/dl)
- Males and Females
- White race
- Sign of the informed consent
Exclusion Criteria:
- Liver insufficiency
- Serious renal disorders
- Diabetes mellitus
- Arterial hypertension
- History or evidence of previous myocardial infarction or other atherothrombotic
diseases
- Any autoimmune diseases
- Cancer
- Present or recent infections
- Patients were taking nonsteroidal antiinflammatory drugs, drugs interfering with
cholesterol metabolism, or vitamin supplements
For T2 Diabetic patients:
Inclusion Criteria:
- Patients with T2DM diagnosed according to the American Diabetes Association
definition
- Treatment with 100 mg/day aspirin from at least 30 days
- Males and Females
- White race
- Sign of the informed consent
Exclusion Criteria:
- recent history (< 3 months) of acute vascular events
- clinical diagnosis of type 1 DM
- serum creatinine level greater than 2. 5 mg/dl
- active infection or malignancy
- cardiac arrhythmia or congestive heart failure
- use of non-steroidal anti-inflammatory drugs, vitamin supplements, or other
antiplatelet drugs such as clopidogrel in the previous 30 days
Locations and Contacts
Stefania Basili, Rome 00161, Italy
Additional Information
Related publications: Carnevale R, Pignatelli P, Di Santo S, Bartimoccia S, Sanguigni V, Napoleone L, Tanzilli G, Basili S, Violi F. Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. Atherosclerosis. 2010 Nov;213(1):225-34. doi: 10.1016/j.atherosclerosis.2010.08.056. Epub 2010 Aug 19. Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C, Basili S, Violi F. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):360-7. doi: 10.1161/ATVBAHA.109.198622. Epub 2009 Dec 3. Erratum in: Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):e20.
Starting date: March 2011
Last updated: May 27, 2015
|